Universal vaccine to treat colds, flu and COVID developed, and a new study suggests it just might work

Vaccines have traditionally worked by teaching the immune system to recognize a specific virus or bacterium—in effect, ...

New Publication Demonstrates Variant-Agnostic Correlate of Protection from COVID-19 for Invivyd Monoclonal Antibody, Useful for Understanding of and Confidence in COVID-19 ...

A Statistical Immune Correlates of Protection Model for Predicting Efficacy from Neutralizing Antibody Titers to Establish Immunobridging of ...
Morning Overview on MSN

New nasal vaccine shields lungs for months from viruses, bacteria, and allergens

Stanford Medicine researchers have developed an experimental nasal vaccine that shielded mouse lungs for at least three months against a striking range of respiratory threats, from SARS-CoV-2 and ...
The Manila Times

Fennec Pharmaceuticals Presents Real World Data Supporting the Integration and Clinical Use of PEDMARK® in Treating Adults with Head & Neck Cancers

Administration of PEDMARK® Approximately Six Hours After Cisplatin was Shown to Be Safe & Easily Integrated into Care for Adults with Head & Neck Cancers (HNC) - ...

Johnson & Johnson: RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line ...

Ten percent complete response and rapid, durable antitumor activity reported with RYBREVANT FASPRO; results surpass current standards of care RARITAN, N.J., Feb. 19 ...
Le Lézard

RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or ...

Johnson & Johnson today announced new results from the Phase 1b/2 OrigAMI-4 study showing that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination ...
PharmiWeb

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for subcutaneous amivantamab and hyaluronidase-lpuj as ...
Agence France-Presse

Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis

Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...

Johnson & Johnson: FDA approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO FDA approval to deliver the simplest and fastest ...
Le Lézard

FDA approves RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved a new, simplified monthly dosing schedule* for RYBREVANT FASPROtm (amivantamab and hyaluronidase-lpuj). When ...

Controversial drug may provide rapid relief from chronic fatigue

Currently, the main approach for easing chronic fatigue is gentle, low-intensity exercise like walking or yoga, which aims to ...
Rutgers University

Ketamine May Fight Chronic Fatigue, Study Suggests

Ketamine, a decades-old anesthetic and fast-acting treatment for severe depression, may also offer some people rapid relief from chronic fatigue, according to a small proof-of-concept study led by ...